Ariad Pharmaceuticals Inc fka ARIA

[LUMA14]

Promising Secondary Endpoints for Ponatinib in CML Despite Early EPIC Trial Termination

link to article

...
“Ponatinib is not an option for first-line therapy at this time,” said Dr Lipton. “But successful completion of the OPTIC studies with a demonstration of reduced toxicity and sustained efficacy may open up the possibility of revisiting another study in newly diagnosed patients.”
...